edward lifesci seek launch strong contend
self-expand tavr nich
page full analyst note may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim
price data jun
rate updat jun
currenc amount express
valuat growth profit
methodolog valu compani
sinc spin baxter
demonstr know stick knit tissu heart
valv edward remain domin forc surgic heart
valv minim invas aortic valv therapi -- one
hottest area cardiac devic
edward done good job refocus higher-margin
product churn meaning innov effort
result impress gross margin
improv sinc becom stand-alon compani although
firm significantli smaller close competitor
abbott term sale remain global leader core
busi tissu heart valv command
global market firm maintain leadership posit
critical-car monitor equip complement heart valv
edward regularli engag serial acquisit
firm recent made seri purchas transcathet mitral
valv technolog order get jump next wave
innov firm posit lead edg
come transcathet heart valv dual aortic franchis
balloon-expand self-expand valv
edward robust transcathet aortic valv pipelin also
lead develop transcathet mitral product edward
pois ride wave new technolog shift valv
replac transcathet approach especi
clinic data support efficaci safeti product
condit
said still anticip bump road
edward alreadi taken shot transcathet mitral valv
littl success challeng area given
econom behind
transcathet aortic valv replac remain less attract
surgic valv mani hospit though eas recent
market also becom crowd
abbott fray nonetheless think
long-term clinic trend shift toward transcathet
technolog edward sit pretti
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
spun design
manufactur market rang medic devic equip
advanc stage heart diseas key product includ surgic tissu
heart valv transcathet valv technolog surgic clip cathet
retractor monitor system use measur patient heart
function surgeri firm deriv total sale
outsid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
edward lifesci seek launch strong
contend self-expand tavr nich may
first-quart result larg match expect
transcathet valv technolog opinion
stand behind fair valu estim think
impend roll-out new self-expand reposition
narrow econom moat edward dug base
intang abil consist bring meaning
innov market clinic data centera
impress mortal stroke paravalvular leak
heart block subsequ need pacemak
implant low level anecdot evid also
suggest practition appreci well centera
perform big wild card perspect
edward price strategi centera price premium
sapien alreadi notch higher
medtron corevalv product find difficult
imagin european countri adopt centera robust
fashion think centera like see enthusiast
recept though regulatori approv isnt
expect
come recent europcr intervent cardiolog
confer data surtavi tavr studi
suggest could see favor result edward
partner trial low-risk patient next spring
case anticip market expans tavr
especi older lower-risk patient struggl
symptomat aortic stenosi nonetheless
continu hold temper view tavr potenti among
toward stay surgic tissu valv durabl
demonstr even beyond year
durabl tavr devic look consist posit
five- six-year mark time
establish durabl tavr year
valuat growth profit
modestli rais fair valu estim
per share adjust sapien
project upward reflect recent
clinic data establish noninferior
corevalv gold-standard surgic valv replac
among intermediate-risk patient take time valu
money account think edward data demonstr
superior sapien savr give leg
competit think data help practition feel
comfort turn transcathet aortic valv
high- intermediate-risk patient expand
patient pool estim patient
importantli think edward eventu captur
subseg high-risk surgic patient
intermediate-risk patient base recent favor
clinic data expect oper margin hold
steadi around effici gener off-set price
pressur competitor enter market
project sapien perform remain heart
valuat expect sapien growth take
account recent strength next-gener
launch new clinic data could sway practition
toward sapien new reimburs code
gone effect transcathet valv franchis
drive averag annual top-lin growth edward
domest price pressur exacerb
expect new entrant emerg may need revisit
assumpt year tax cut also
signific driver bottom-lin project
firm effect tax rate fall initi
estim total think adjust net incom
increas compound annual
versu trail three year period
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
would reach billion oper
margin would peak assumpt
would see top-lin growth price pressur
requir invest research develop
would keep earn growth averag would
slice valuat per share
despit compet rather matur surgic heart valv
market come domin tissu
valv thu dig narrow moat compani long
histori pioneer new heart valv still highli
regard cardiac surgeon technolog advanc
edward compet abbott primarili mechan heart
valv howev edward remain
heavi hitter tissu valv segment like mani
devic compani edward compet basi
technolog innov intellectu properti close
relationship physician
recent edward
forg ahead
technolog innov give heart valv market
jolt develop minim invas aortic heart valv
instal cathet therebi make
procedur recoveri much easier patient current
tradit valv requir extens surgic procedur
implant mean estim half one third
elderli patient need valv replac
frail high-risk undergo surgic valv replac
believ edward bolster leadership posit
tissu heart valv sapien transcathet aortic valv
franchis tavr deliv either
femor arteri similar angioplasti small
hole two rib minim invas therapi
would potenti tap estim american
patient current
inoper high-risk
candid tradit valv surgeri expect
technolog adopt wide patient pool
expand includ intermediate- low-risk patient
base rel narrow concentr product
portfolio edward rate firm uncertainti high
recogn may substanti upsid patient
pool tavr expand includ intermediate-
low-risk patient addit competit europ remain
peripher reimburs europ quicken
case sketch bull scenario abbott
boston unabl grow major tavr rival
heart-rhythm
complic associ corevalv condit
would drive tavr sale nearli billion
oper margin would hover
averag annual revenu growth adjust earn
growth scenario bring fair valu
estim per share
address
unabl
hand see share loss abbott
boston scientif along
aggress price pressur -- expect growth
transcathet aortic valv sale sapien franchis sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
time trial data amass
stand behind stabl moat trend rate
edward expect continu technolog innov
help counter grow threat competit
edward global leader surgic tissu heart valv
less invas technolog put ahead
competitor edward two-year lead pioneer
categori transcathet heart valv -- one hottest
develop excit intervent cardiologist
heart surgeon alik addit edward alreadi
launch next-gener sapien ultra well
consist improv upon transcathet product
enhanc make even thinner easier
faster use virtual elimin sever valve-leakag
complic affect patient
earlier technolog compani success
develop transcathet mitral valv technolog think
transcathet valv
everywher formid competitor
key geographi includ st jude medic
part abbott present europ
enter next year two despit
edward head start geographi firm
need offer meaning innov regular basi
keep leadership posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oedward effort focu effici higher-
margin product paid gross margin
increas
ocardiothorac surgeon fairli conserv
bunch like stick proven devic brand
pioneer heart valv edward continu
seen gold standard
oedward benefit age popul
experi problem heart valv
congest heart failur greater frequenc
oedward ambit diversifi
minim
invas medic technolog place firm direct
competit much larger competitor
abbott easili bid price
emerg technolog edward
ocompetit abbott like
enter market start late
oif sapien price remain high even entranc
new rival payer may limit usag transcathet
valv intermediate-risk patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
edward light debt leverag larg cash invest
posit give firm financi flexibl end
decemb edward major debt outstand
consist roughli billion senior unsecur note
million matur mean time
firm sat billion cash invest
follow recent cardiaq valtech acquisit
bolster mitral valv pipelin gross debt/ebitda stood
time interest coverag
time view share repurchas like use
edward excess financi resourc time
manag indic prudent prefer make
repurchas time share look attract
valu marketplac edward spent
approxim million repurchas compani
pay dividend merger acquisit
typic use intern research develop effort
smaller acquisit expand product offer
purchas variou transcathet mitral
valv technolog edward ride high growth
wave transcathet aortic valv expect
abl easili fund growth support strateg
acquisit financi resourc cash flow
unless firm becom enamor larg acquisit
opportun someth view unlik
anticip major chang easili manag capit
base rel narrow concentr product
portfolio edward rate firm uncertainti
high volum edward heart valv still requir
major surgeri implant medic industri
move toward minim invas procedur
cut recoveri time cost although edward
current enjoy duopoli transcathet aortic valv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
 new competitor
horizon boston scientif still work lotu
transcathet valv recent acquir new
self-expand tavr technolog though think boston
trail edward year firm
prove fierc competitor cardiac devic
market clinic outcom sapien valv
longer term yet assess durabl
product meet exceed track record surgic
valv clinician may wari use product
younger patient addit preliminari data hint
substanti portion elderli patient popul
would expir anyway independ caus
within sever year even implant sapien valv
rais question medicar appetit
reimburs expens devic put pressur tavr
manufactur demonstr econom valu
technolog final edward could see competit
surgic tool busi minim invas surgic
system maker enter cardiac
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
govern pension fund norway global
share
fund
share
fund
think edward stewardship solid assign
presid baxter michael mussallem ceo
chairman edward sinc spin-off offer
steadi presenc helm mussallem receiv
reason compens like goal
bonu place emphasi revenu growth free
cash flow growth net incom also taken
consider think often subject
would like see even greater detail specif
measur mussallem judg would prefer
see free cash flow gener weight heavili
net incom growth pleas edward reli
restricted-stock unit vest five year rather
stock option alon encourag mussallem
manag edward eye toward longer term
like succession-plan updat provid
board meet ensur board highli involv
survey manag talent potenti execut
posit think firm overal corpor govern
polici well design
corporate-alloc standpoint edward made
wise decis unlik larger rival edward
reli heavili serial acquisit instead
first prioriti plow resourc intern innov
kept surgic heart valv busi
leadership posit support consist
meaning innov transcathet aortic valv
portfolio one major earli acquisit edward made
percutan valv million
includ mileston payment laid
foundat edward sapien technolog addit
pvt catapult edward race enter tavr
market first edward might lucki
purchas mani early-stag technolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
end gutter ball nevertheless edward enjoy
strong posit categori project grow
billion edward recent acquisit cardiaq
harpoon valtech bolster firm invest
transcathet mitral valv therapi even though
commerci technolog could take year
think edward strong posit pursu market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
come quarter give us earli peek recept
practition technolog whether
ease-of-us issu emerg
develop transcathet mitral valv technolog
key cardiac devic maker pursu innov
pleas see report chang heart renew interest
among cardiac devic maker transcathet mitral
edward lifesci pois anoth year
robust growth thank tavr feb
edward lifesci finish strong fashion
expect moder rais fair valu estim
reflect margin expans favor product mix
shift lower-than-expect effect tax rate
well time valu money remain confid
edward narrow econom moat firm prepar
launch sapien ultra deliveri system europ
 year european regulatori approv
centera self-expand tavr product firm remain
lead edg tavr innov addit
centera offer broadest rang tavr devic
edward full-year result close estim
top bottom line sale growth
transcathet heart valv consist
project surgic valv critic care
slightli exceed estim though
materi factor move valuat project
continu double-digit growth tavr franchis
put estim total revenu growth near
top manag outlook pleas hear
 contribut
disproportion quarterli tavr growth
addit new center slow
significantli adopt technolog increas
patient volum key factor support robust
growth go forward contend recent indic
expans includ intermediate-risk eventu low-
risk patient keep underli demand healthi
although commerci transcathet mitral valv
technolog remain edward make
progress rang tmv platform enrol
 trial cardioband continu enrol
pascal expect begin later year given
cardioband alreadi approv use europ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
